Single-agent topotecan as first-line chemotherapy in women with metastatic breast cancer: Final results of Eastern Cooperative Oncology Group trial E8193

Clinical Breast Cancer

Volumn 6, Issue 4, 2005, Pages 334-339

  Wolff, Antonio C ^a   O'Neill, Anne ^b   Kennedy, M John ^a,g   Stewart, James A ^c   Gradishar, William J ^d   Lord III, Raymond S ^e   Davidson, Nancy E ^a   Wood, William C ^f  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e West Michigan Cancer Center   (United States)

^f EMORY UNIVERSITY   (United States)

^g ST JAMES S HOSPITAL   (Ireland)

Author keywords

Camptothecin analogues; Hematopoietic toxicity; Topoisomerase I inhibitor

Indexed keywords

NAVELBINE; TOPOTECAN; TUMOR MARKER;

ADULT; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLEEDING DISORDER; BODY WEIGHT DISORDER; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONTINUOUS INFUSION; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FEVER; DRUG INFUSION; DRUG RESPONSE; DRUG TOLERABILITY; FATIGUE; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; INFECTION; LIVER TOXICITY; LUNG TOXICITY; METABOLIC DISORDER; METASTASIS POTENTIAL; MONOTHERAPY; MULTICENTER STUDY; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PHLEBITIS; PNEUMONIA; PROGNOSIS; SIDE EFFECT; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT PLANNING; WEIGHT REDUCTION;

EID: 28344457209     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2005.n.037     Document Type: Article

References (37)

1. Costanza ME, Weiss RB, Henderson IC, et al. Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study - Cancer and Leukemia Group B 8642. J Clin Oncol 1999; 17:1397-1406.
2. Wall ME, Wani MC, Cook CE, et al. Plant antitumor agents: I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 1966; 88:3888-3890.
3. Gellert M. DNA topoisomerases. Annu Rev Biochem 1981; 50:879-910.
4. Eng WK, Faucette L, Johnson RK, et al. Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin. Mol Pharmacol 1988; 34:755-760.
5. Gottlieb JA, Guarino AM, Call JB, et al. Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). Cancer Chemother Rep 1970; 54:461-470.
6. Muggia FM, Creaven PJ, Hansen HH, et al. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemother Rep 1972; 56:515-521.
7. Creaven PJ, Allen LM, Muggia FM. Plasma camptothecin (NSC-100880) levels during a 5-day course of treatment: relation to dose and toxicity. Cancer Chemother Rep 1972; 56:573-578.
8. Gottlieb JA, Luce JK. Treatment of malignant melanoma with camptothecin (NSC-100880). Cancer Chemother Rep 1972; 56:103-105.
9. Moertel CG, Schutt AJ, Reitemeier RJ, et al. Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep 1972; 56:95-101.
10. Slichenmyer WJ, Rowinsky EK, Donehower RC, et al. The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 1993; 85:271-291.
11. Arbuck SG, Takimoto CH. An overview of topoisomerase I-targeting agents. Semin Hematol 1998; 35:3-12.
12. Bookman MA, Malmstrom H, Bolis G, et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol 1998; 16:3345-3352.
13. von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999; 17:658-667.
14. Burris HA III, Awada A, Kuhn JG, et al. Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusion. Anticancer Drugs 1994; 5:394-402.
15. Levine EG, Cirrincione CT, Szatrowski TP, et al. Phase II trial of topotecan in advanced breast cancer: a Cancer and Leukemia Group B study. Am J Clin Oncol 1999; 22:218-222.
16. Rowinsky EK, Grochow LB, Hendricks CB, et al. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J Clin Oncol 1992; 10:647-656.
17. Oberhoff C, Kieback DG, Wurstlein R, et al. Topotecan chemotherapy in patients with breast cancer and brain metastases: results of a pilot study. Onkologie 2001; 24:256-260.
18. Burris HA III, Hanauske AR, Johnson RK, et al. Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro. J Natl Cancer Inst 1992; 84:1816-1820.
19. Thall PF, Simon R, Ellenberg SS. A two-stage design for choosing among several experimental treatments and a control in clinical trials. Biometrics 1989; 45:537-547.
20. Mehta CR, Patel NR. A network algorithm for the exact treatment of Fisher's exact test in rxc contingency tables. J Am Stat Assoc 1983; 78:427-434.
21. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-481.
22. Critical role of phase I clinical trials in cancer treatment. American Society of Clinical Oncology. J Clin Oncol 1997; 15:853-859.
23. Rowinsky EK. Weekly topotecan: an alternative to topotecan's standard daily × 5 schedule? Oncologist 2002; 7:324-330.
24. Armstrong D, O'Reilly S. Clinical guidelines for managing topotecan-related hematologic toxicity. Oncologist 1998; 3:4-10.
25. O'Reilly S. Topotecan: what dose, what schedule, what route? Clin Cancer Res 1999; 5:3-5.
26. Gerrits CJ, Schellens JH, Burris H, et al. A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin). Clin Cancer Res 1999; 5:69-75.
27. Perez EA, Hillman DW, Mailliard JA, et al. Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both. J Clin Oncol 2004; 22:2849-2855.
28. Taguchi T, Yoshida Y, Izuo M, et al. An early phase II study of CPT-11 (irinotecan hydrochloride) in patients with advanced breast cancer. Gan To Kagaku Ryoho 1994; 21:83-90.
29. Humerickhouse R, Lohrbach K, Li L, et al. Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. Cancer Res 2000; 60:1189-1192.
30. Ratain MJ. Irinotecan dosing: does the CPT in CPT-11 stand for "Can't Predict Toxicity"? J Clin Oncol 2002; 20:7-8.
31. Innocenti F, Undevia SD, Iyer L, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004; 22:1382-1388.
32. McLeod HL, Watters JW. Irinotecan pharmacogenetics: is it time to intervene? J Clin Oncol 2004; 22:1356-1359.
33. Rowinsky EK, Rizzo J, Ochoa L, et al. A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies. J Clin Oncol 2003; 21:148-157.
34. Rowinsky EK, Johnson TR, Geyer CE Jr, et al. DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies. J Clin Oncol 2000; 18:3151-3163.
35. Sharma S, Kemeny N, Schwartz GY, et al. Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeks. Clin Cancer Res 2001; 7:3963-3970.
36. Esteva FJ, Rivera E, Cristofanilli M, et al. A Phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma. Cancer 2003; 98:900-907.
37. Stearns V, Davidson NE, Flockhart DA. Pharmacogenetics in the treatment of breast cancer. Pharmacogenomics J 2004; 4:143-153.